
Medidata has launched a new offering called ‘Medidata Patient Payments’ designed to simplify the process of providing stipends and reimbursements to people taking part in clinical research.
This solution is aimed at addressing the challenge of compensating the subjects for their effort, time and expenses related to the studies.
The introduction of Medidata Patient Payments aims to enhance the patient experience by offering an intuitive platform for submitting reimbursement requests.
It covers a range of expenses such as meals, travel, lodging, childcare, lost wages, and mileage.
The solution leverages the Medidata Platform to automate the payment lifecycle, triggering stipends based on trial activities such as diary completion or assessments.
This integrated offering supports quick implementation and is tailored to meet the preferences of both patients and study sites.

US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataPatient Payments also provides unified access through myMedidata for subjects and iMedidata for sites and sponsors.
Being part of a comprehensive e-clinical suite, the offering allows for integration and the generation of actionable insights throughout the study lifecycle.
Medidata clinical trial financial management vice-president Meghan Harrington said: “Our Patient Payments solution is a direct reflection of the commitment and passion we have to deliver an extraordinary patient experience.
“Our partnerships with Medidata’s patient and site advisory boards, coupled with the incomparable data housed within our ecosystem, provides us with a unique opportunity to modernise the financial management experience for patients.”
In June, Medidata introduced Clinical Data Studio, an AI-powered platform that aims to transform the clinical research data experience to streamline trials.
This offering provides stakeholders enhanced control over data quality and the ability to conduct safer trials more swiftly.